Alzheimer’s disease (AD) is an age-associated neurodegenerative disease (ND) affecting social and behavioral activities. Prevalence studies indicate that the global AD population will proliferate to 114 million by 2050. Presently, AD remains incurable, and the high failure rate of clinical trials for AD-related drugs has raised the need to understand the molecular mechanisms of AD. Besides, there is utmost need for developing novel drugs as therapeutics and theranostic approaches for early detection of AD progression and targeting the molecular level brain delivery of small molecules using nanocapsules as therapeutics for AD. Using the advanced technology for the treatment of AD in diagnostics, brain delivery, and therapeutics would bring out a solution for the bench to bedside in AD therapy.
The application of advanced technology in drug discovery, diagnostics, and brain delivery systems has been flourishing in recent years for the remedy of Alzheimer’s disease. Inter-disciplinary approaches and strategies have helped to understand the prognosis and pathogenesis of Alzheimer’s disease (AD). Unfortunately, there are no single confirmatory tests or diagnostics that can clinically be used to identify and determine the presence or absence of Alzheimer’s pathology. Therefore, AD has posed tremendous challenges for researchers in the scientific community and medical experts to tackle the unresolved issues in early detection, diagnostics, and therapeutics for AD.
This Research Topic welcomes contributions, in the form of original research articles or reviews and opinions, to address/summarize challenges and comprehensions of the diagnostics, brain delivery, and therapeutics in AD therapy.
• Diagnostic probes for the early detection of Alzheimer’s disease
• Exosomes and their role in Alzheimer’s Disease prognosis and therapy
• Brain delivery systems for the Alzheimer’s disease therapy
• Autophagy inducers and Phytochemicals for Alzheimer’s disease
• Advanced insights into molecular mechanisms in Alzheimer’s disease
Alzheimer’s disease (AD) is an age-associated neurodegenerative disease (ND) affecting social and behavioral activities. Prevalence studies indicate that the global AD population will proliferate to 114 million by 2050. Presently, AD remains incurable, and the high failure rate of clinical trials for AD-related drugs has raised the need to understand the molecular mechanisms of AD. Besides, there is utmost need for developing novel drugs as therapeutics and theranostic approaches for early detection of AD progression and targeting the molecular level brain delivery of small molecules using nanocapsules as therapeutics for AD. Using the advanced technology for the treatment of AD in diagnostics, brain delivery, and therapeutics would bring out a solution for the bench to bedside in AD therapy.
The application of advanced technology in drug discovery, diagnostics, and brain delivery systems has been flourishing in recent years for the remedy of Alzheimer’s disease. Inter-disciplinary approaches and strategies have helped to understand the prognosis and pathogenesis of Alzheimer’s disease (AD). Unfortunately, there are no single confirmatory tests or diagnostics that can clinically be used to identify and determine the presence or absence of Alzheimer’s pathology. Therefore, AD has posed tremendous challenges for researchers in the scientific community and medical experts to tackle the unresolved issues in early detection, diagnostics, and therapeutics for AD.
This Research Topic welcomes contributions, in the form of original research articles or reviews and opinions, to address/summarize challenges and comprehensions of the diagnostics, brain delivery, and therapeutics in AD therapy.
• Diagnostic probes for the early detection of Alzheimer’s disease
• Exosomes and their role in Alzheimer’s Disease prognosis and therapy
• Brain delivery systems for the Alzheimer’s disease therapy
• Autophagy inducers and Phytochemicals for Alzheimer’s disease
• Advanced insights into molecular mechanisms in Alzheimer’s disease